Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant
I. A. Favorskaya, D. V. Shcheblyakov, I. B. Esmagambetov, I. V. Dolzhikova, I. A. Alekseeva, A. I. Korobkova, D. V. Voronina, E. I. Ryabova, A. A. Derkaev, A. V. Kovyrshina, A. A. Iliukhina, A. G. Botikov, O. L. Voronina, D. A. Egorova, O. V. Zubkova, N. N. Ryzhova, E. I. Aksenova, M. S. Kunda, D. Y. Logunov, B. S. Naroditsky, A. L. Gintsburg
Abstract
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants
- A potent SARS-CoV-2 neutralizing antibody recognizing a conserved epitope with broad mutant variant and SARS-CoV activity.
A. J. Pelzek, S. Ebtehaj, … S. P. Murphy·bioRxiv·Feb 6, 2022
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Y. Weisblum, F. Schmidt, … P. D. Bieniasz·bioRxiv·Jul 21, 2020
- Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron)
M. Imbrechts, W. Kerstens, … N. Geukens·bioRxiv·Dec 21, 2021
- An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
W. Du, D. L. Hurdiss, … B. J. Bosch·bioRxiv·Feb 17, 2022
- Novel monoclonal antibodies showing broad neutralizing activity for SARS-CoV-2 variants including Omicrons BA.5 and BA.2.75
H. Ishimaru, M. Nishimura, … Y. Mori·bioRxiv·Sep 2, 2022